Factor 8 SHL denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for factor 8 shl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Factor VIII (SHL) for Medical Necessity

A medical-necessity denial from Blue Cross Blue Shield means their clinical reviewer determined that the documentation submitted did not adequately establish that the extended half-life (SHL) Factor VIII product was required for your condition, compared to less costly or more established alternatives.

This denial is among the most commonly overturned on appeal, particularly when the treating hematologist provides detailed, individualized clinical justification. The key is converting a general prescription into a patient-specific, evidence-anchored narrative.

## Federal Appeal Rights

• ERISA §503 (employer-sponsored plans): full-and-fair internal review by a qualified clinical reviewer not involved in the original decision.
• ACA §2719 (non-grandfathered plans): binding independent external review by an accredited IRO if the internal appeal is denied.
• You generally have approximately four months from the denial date to request external review.
• Expedited option: request simultaneous expedited internal and external review if your physician certifies that the standard timeline poses a serious health risk.

## Concrete Appeal Timeline

1. Request the clinical criteria used in the denial decision (BCBS must provide these). 2. Have your hematologist prepare a point-by-point medical-necessity letter. 3. Submit the internal appeal with all supporting records. 4. If upheld, file for external review without delay.

## Documentation to Gather

• Diagnosis confirmation: complete hematology records with FVIII activity levels, inhibitor testing results, and severity classification per your chart.
• Annualized bleed rate (ABR): chart-documented bleed history, including joint, muscle, and spontaneous bleeds, with dates and locations.
• Prior treatment history with outcomes: all previous Factor VIII products tried, dates of use, doses (per your chart — not to be stated generically), and documented outcomes including treatment failures or breakthrough bleeds.
• Pharmacokinetic (PK) data: if individual PK profiling was performed, include the results and the hematologist's interpretation explaining why SHL is required for adequate trough levels with an acceptable infusion schedule.
• Functional and quality-of-life impact: documentation of joint damage (imaging reports), pain scales, school/work absences, and infusion burden on a standard half-life regimen.
• Prescriber medical-necessity letter: must address each criterion in BCBS's medical policy for SHL Factor VIII specifically — not a generic hemophilia letter.

## Criteria-Mapping Structure

Obtain the specific BCBS Coverage Medical Policy for extended half-life Factor VIII products and map each stated criterion to chart evidence:

| BCBS Policy Requirement | Supporting Chart Fact | |---|---| | Confirmed hemophilia A diagnosis with documented severity | [Lab values from your chart, dated] | | Trial or documented consideration of standard half-life Factor VIII | [Dates, products, and outcomes per medical record] | | PK justification or clinical rationale for extended half-life | [PK study result or hematologist's individualized rationale] | | Prescribing by qualified hematologist | [Treating provider credentials] |

Always verify the exact eligibility requirements from BCBS's current published medical policy and from the FDA-approved prescribing label for the specific Factor VIII SHL product. Requirements change; your appeal must address the criteria in effect at the time of denial.